ISSN: 1520-9156

Journal Home

Journal Guideline

Diabetes Technology and Therapeutics Q1 Unclaimed

Mary Ann Liebert Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Diabetes Technology and Therapeutics is a journal indexed in SJR in Medicine (miscellaneous) and Endocrinology with an H index of 97. It has an SJR impact factor of 2,374 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,374.

Diabetes Technology and Therapeutics focuses its scope in these topics and keywords: diabetes, type, mellitus, patients, health, glucose, extended, adult, longstanding, liabilities, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Endocrinology (Q1) Endocrinology, Diabetes and Metabolism (Q1) Endocrinology, Diabetes and Metabolism (Q1) Medical Laboratory Technology (Q1) Medicine (miscellaneous) (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

2,374

SJR Impact factor

97

H Index

140

Total Docs (Last Year)

421

Total Docs (3 years)

3367

Total Refs

2273

Total Cites (3 years)

384

Citable Docs (3 years)

5.24

Cites/Doc (2 years)

24.05

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Annual Review of Public Health Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Annual Review of Clinical Psychology Q1
JAMA - Journal of the American Medical Association Q1

Compare this journals

Aims and Scope

Best articles by citations

Public Adventures in Diabetes: Personal Interactivity in a Modern Science Center

Pilot Clinical Study of an Endoscopic, Removable Duodenal-Jejunal Bypass Liner for the Treatment of Type 2 Diabetes

Fluorescence Resonance Energy Transfer-Based Near-Infrared Fluorescence Sensor for Glucose Monitoring

Impact of Family History of Diabetes on beta-Cell Function and Insulin Resistance Among Chinese with Normal Glucose Tolerance

A 2-Year Pilot Trial of Continuous Subcutaneous Insulin Infusion Versus Intensive Insulin Therapy in Patients with Newly Diagnosed Type 1 Diabetes (IMDIAB 8)

Evaluation of a New Insulinotropic Agent by Using an Innovative Technology: Efficacy and Safety of Nateglinide Determined by Continuous Glucose Monitoring

Non-Invasive Imaging of Beta Cell Mass: A Quantitative Analysis

High Glycemic Variability Assessed by Continuous Glucose Monitoring After Surgical Treatment of Obesity by Gastric Bypass

Relating Glucose Clamp Profiles to Reduction of Blood Glucose After Insulin Administration

A Prospective, Randomized, Multicentered Controlled Trial to Compare the Annual Outcomes of Patients with Diabetes Mellitus Monitored with Weekly Fructosamine Testing Versus Usual Care: A 3-Month Interim Analysis

Total Energy Expenditure Estimated Using Foot-Ground Contact Pedometry

Accessibility of Insulin Pumps for Blind and Visually Impaired People

SHOW MORE ARTICLES

Diabetes Calendar

Safety of Contact Lenses in Patients with Diabetes

Highlights of NIDDK's Translational Diabetes and Obesity Research Conference

Introduction

Reduced Severe Hypoglycemia with Insulin Glargine in Intensively Treated Adults with Type 1 Diabetes

Bioenergetics of Animal Locomotion: Lessons for Expedient Monitoring in Human Fitness and Weight Management

The Validity of the Medisafe Self-Monitoring Blood Glucose System

Effect of High Altitude on Blood Glucose Meter Performance

Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers

Technosphere‚Ñ¢/Insulin - A New Approach for Effective Delivery of Human Insulin Via the Pulmonary Route

Analysis: A Nurse Educator's Perspective on the Innovo¬Æ Insulin Delivery System